Sociedad Americana de Hirudoterapia

Quality of Life after Venous Stenting for Post-thrombotic Syndrome and the Effect of Inflow Disease.

Research article published in Vascular and endovascular surgery (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosSeguridad y control de infeccionesBakas JM et al. · Vascular and endovascular surgery, 2023

Abstract

OBJECTIVE: Patients with PTS experience an impaired quality of life (QoL). We aimed to study QoL in patients stented for post thrombotic syndrome (PTS) and analyze the influence of different parameters. METHODS: Patients stented for PTS after iliofemoral deep vein thrombosis were asked to complete the Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-20) and the Short Form Health Survey (SF-36) in this cross-sectional study. All other data were collected retrospectively. Primary endpoints were median CIVIQ-20 and physical (PCS) and mental (MCS) component summary SF-36 scores. The influence of age, sex, and years between the procedure and completion of questionnaire were investigated using a multivariate linear regression model. Wilcoxon signed rank test compared the PCS and MCS with the normative. Effects of inflow from the deep femoral vein (DFV) and/or the femoral vein (FV) on QoL was analyzed in patients with patent stents. RESULTS: The response rate was 70.3% (n = 45/64). Time period (median) from stenting to questionnaire completion was 6.6 years (IQR: 8.0). Most stents were placed unilateral left-sided (73.3%). For patients with patent stents (n = 42) median CIVIQ-20 was 35.5 (IQR: 17.3), higher than the minimum of 20.0 (P < .001). Median PCS of 44.7 (IQR: 14.2) was lower (P < .001), and MCS of 55.9 (IQR: 7.1) higher (P = .001) than the normative (50.0). Time since stenting and sex were not associated with QoL. Age was a significant predictor [standardized coefficient ß = .36, P = .04] for QoL using the CIVIQ-20, but not for the SF-36. Inflow disease did not impact QoL, but patients with occluded stents (n = 3) had poor functioning levels. CONCLUSION: Quality of life is impaired after venous stenting for PTS, particularly physical functioning, among patients with an open stent, but was similar between patients with good and impaired inflow. Patients with a permanent stent occlusion had the lowest QoL.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansQuality of LifeFemaleMalePostthrombotic SyndromeStentsMiddle AgedCross-Sectional StudiesTreatment OutcomeRetrospective StudiesFemoral VeinTime Factors

Resumen

Patients with PTS experience an impaired quality of life (QoL). We aimed to study QoL in patients stented for post thrombotic syndrome (PTS) and analyze the influence of different parameters.

Por qué esto importa para la hirudoterapia

Este estudio transversal evaluó la calidad de vida en 45 de 64 pacientes elegibles (70.3% de respuesta) una mediana de 6.6 años después de la implantación de un stent venoso por síndrome postrombótico tras una trombosis venosa profunda iliofemoral, utilizando el CIVIQ-20 y el SF-36; encontró una calidad de vida persistentemente deteriorada, particularmente en la función física (resumen del componente físico mediano de 44.7 frente a un valor normativo de 50.0, p<0.001), siendo la edad un predictor significativo en el CIVIQ-20 pero la enfermedad de flujo de entrada sin mostrar ningún efecto, mientras que los tres pacientes con stents ocluidos presentaron la peor evolución. Para la ASH, documenta la morbilidad duradera que deja la tromboembolia venosa incluso después del tratamiento estructural, subrayando por qué el campo anticoagulante/antitrombótico más amplio (al que pertenece el secretoma de la sanguijuela) es clínicamente relevante. Advertencia: se trata de una encuesta transversal, retrospectiva, unicéntrica y pequeña, sin tratamiento de comparación ni relación con la terapia con sanguijuelas; describe la carga de la enfermedad, no ninguna intervención de hirudoterapia.

Citación

Quality of Life after Venous Stenting for Post-thrombotic Syndrome and the Effect of Inflow Disease.

Bakas JM et al. · Vascular and endovascular surgery, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.